Cartesian Therapeutics CTO Transition to Consultant Role

Cartesian Therapeutics ( (RNAC) ) has issued an update.

On April 29, 2025, Cartesian Therapeutics, Inc. announced that its Chief Technology Officer, Metin Kurtoglu, will end his employment with the company on May 1, 2025. Following this, he will transition to a consulting role from May 1, 2025, to April 30, 2026. The agreements include a separation deal where Dr. Kurtoglu will release any claims against the company in exchange for severance benefits, including 12 months’ salary, a pro-rated bonus, and accelerated vesting of equity awards.

Spark’s Take on RNAC Stock

According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral.

RNAC’s overall stock score reflects significant financial and technical challenges, including declining revenues, negative equity, and weak technical indicators. However, recent positive developments in clinical trials offer potential upside. Despite these advancements, substantial financial risks and unfavorable valuation metrics weigh heavily on the stock’s overall assessment.

To see Spark’s full report on RNAC stock, click here.

More about Cartesian Therapeutics

YTD Price Performance: -27.88%

Average Trading Volume: 95,143

Technical Sentiment Signal: Buy

Current Market Cap: $316.3M

For a thorough assessment of RNAC stock, go to TipRanks’ Stock Analysis page.